Provided by Tiger Trade Technology Pte. Ltd.

MediciNova

1.78
+0.15009.20%
Post-market: 1.920.1400+7.87%19:30 EDT
Volume:275.01K
Turnover:493.29K
Market Cap:87.48M
PE:-8.14
High:1.84
Open:1.67
Low:1.67
Close:1.63
52wk High:3.90
52wk Low:1.17
Shares:49.15M
Float Shares:43.50M
Volume Ratio:0.44
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2188
EPS(LYR):-0.2445
ROE:-25.56%
ROA:-16.41%
PB:2.35
PE(LYR):-7.28

Loading ...

MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer

MT Newswires Live
·
Jun 08

Medicinova - Patent Expected to Expire No Earlier Than September 2042

THOMSON REUTERS
·
Jun 08

Medicinova - Receives U.S. Patent Notice for Mn-166 With Anti-Pd-1 in Glioblastoma

THOMSON REUTERS
·
Jun 08

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

GlobeNewswire
·
Jun 08

Analysts’ Top Healthcare Picks: Coherus Biosciences (CHRS), Medicinova (MNOV)

TIPRANKS
·
May 29

Analyst Initiates Buy on MediciNova, Citing Pivotal Tipelukast and Ibudilast Catalysts to Support $10 Price Target

TIPRANKS
·
May 28

MediciNova completes Phase 2 trial last patient visit for MN-001 in NAFLD, hypertriglyceridemia linked to type 2 diabetes

Reuters
·
May 27

Medicinova Announces Completion of Last Patient Last Visit in the Mn-001-Natg-202 Clinical Trial of Mn-001 (Tipelukast)

THOMSON REUTERS
·
May 27

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewswire
·
May 27

MediciNova Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

MediciNova Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 08

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 04

MediciNova’s peer-reviewed ibudilast study advances clinical translation

TIPRANKS
·
Apr 28

MediciNova plans clinical studies of ibudilast for brain metastases after CNIO findings

Reuters
·
Apr 28

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

GlobeNewswire
·
Apr 28

MediciNova announces annual shareholder meeting

Reuters
·
Apr 18